long intergenic non-protein coding RNA 993 (LINC00993)

LINC00993 (long intergenic non-protein coding RNA 993) is a human long non-coding RNA (lncRNA) transcribed from chromosome 10 (10p11.21), classified as a transcribed unprocessed pseudogene[1][9][10][11]. It is predominantly expressed in the nucleus and is notably downregulated in triple-negative breast cancer (TNBC)[2][4]. Studies show that LINC00993 acts as a tumor suppressor in TNBC by inhibiting cell proliferation, halting the cell cycle (G0/G1 arrest), and promoting apoptosis. Overexpression of LINC00993 upregulates cell cycle inhibitors (such as p16^INK4A^, p14^ARF^, p53, p21) and inhibits key proliferation pathways, possibly through its interaction with the RNA-binding protein hnRNPA1[4]. LINC00993 also participates in the regulation of genes involved in chromosome segregation, nuclear division, and microtubule motor activity, according to gene ontology analyses[4]. Currently, it is not considered a classical therapeutic target (like a receptor, enzyme, or transporter), nor are there any drugs known to act via or on LINC00993[1][2][4]. However, its strong prognostic value and tumor-suppressive effects suggest it may serve as a potential biomarker and possible future target for developing therapies in breast cancer, especially the triple-negative subtype[2][4].

Other names

LINC00993TCONS_l2_0000297310p11.21RP11-20F24.4